1. Home
  2. NREF vs ZNTL Comparison

NREF vs ZNTL Comparison

Compare NREF & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

HOLD

Current Price

$13.85

Market Cap

244.2M

Sector

Real Estate

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$6.59

Market Cap

195.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NREF
ZNTL
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.2M
195.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NREF
ZNTL
Price
$13.85
$6.59
Analyst Decision
Hold
Buy
Analyst Count
2
5
Target Price
$14.00
$5.80
AVG Volume (30 Days)
60.5K
1.1M
Earning Date
04-30-2026
05-13-2026
Dividend Yield
14.41%
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.79
N/A
P/E Ratio
$4.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.36
$1.13
52 Week High
$16.06
$4.50

Technical Indicators

Market Signals
Indicator
NREF
ZNTL
Relative Strength Index (RSI) 52.59 87.82
Support Level $13.38 $1.31
Resistance Level $14.39 N/A
Average True Range (ATR) 0.40 0.48
MACD 0.11 0.34
Stochastic Oscillator 79.04 94.98

Price Performance

Historical Comparison
NREF
ZNTL

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: